Wells Fargo’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-74,447
| Closed | -$3.57M | – | 7249 |
|
|
2020
Q1 | $3.57M | Sell |
74,447
-29,822
| -29% | -$1.39M | ﹤0.01% | 2519 |
|
|
2019
Q4 | $4.89M | Buy |
104,269
+27,904
| +37% | +$1.23M | ﹤0.01% | 2586 |
|
|
2019
Q3 | $1.81M | Buy |
76,365
+28,730
| +60% | +$851K | ﹤0.01% | 3418 |
|
|
2019
Q2 | $1.43M | Buy |
47,635
+12,010
| +34% | +$275K | ﹤0.01% | 3618 |
|
|
2019
Q1 | $798K | Sell |
35,625
-10,355
| -23% | -$223K | ﹤0.01% | 4041 |
|
|
2018
Q4 | $837K | Buy |
45,980
+38,385
| +505% | +$603K | ﹤0.01% | 3975 |
|
|
2018
Q3 | $137K | Sell |
7,595
-43,492
| -85% | -$515K | ﹤0.01% | 5206 |
|
|
2018
Q2 | $508K | Buy |
51,087
+35,874
| +236% | +$248K | ﹤0.01% | 4441 |
|
|
2018
Q1 | $81K | Sell |
15,213
-7,478
| -33% | -$53.4K | ﹤0.01% | 5400 |
|
|
2017
Q4 | $193K | Sell |
22,691
-1,151
| -5% | -$14.2K | ﹤0.01% | 4972 |
|
|
2017
Q3 | $348K | Buy |
23,842
+14,885
| +166% | +$225K | ﹤0.01% | 4581 |
|
|
2017
Q2 | $168K | Sell |
8,957
-498
| -5% | -$11.2K | ﹤0.01% | 4889 |
|
|
2017
Q1 | $202K | Buy |
9,455
+5,700
| +152% | +$109K | ﹤0.01% | 4813 |
|
|
2016
Q4 | $57K | Buy |
+3,755
| New | +$51K | ﹤0.01% | 5348 |
|
Other funds holding RARX
Wells Fargo's RARX Position: Q2 2020 in Review
Wells Fargo sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 74,447 shares — an estimated $3.57M sold.
Wells Fargo first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $4.89M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Wells Fargo reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Wells Fargo sold 74,447 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $3.57M.
- Wells Fargo first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Wells Fargo's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.89M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Wells Fargo's 13F filing for Q2 2020, filed 13 Aug 2020.